Education
About Us
Working with TipRanks
Follow Us
Iovance Biotherapeutics Inc (IOVA)
NASDAQ:IOVA
IOVA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.64 - $12.51
Previous CloseN/A
Volume2.95M
Average Volume (3M)11.36M
Market Cap
$767.13M
Enterprise Value$327.34M
Total Cash (Recent Filing)$301.18M
Total Debt (Recent Filing)$53.17M
Price to Earnings (P/E)―
Beta2.11
Next Earnings
Nov 06, 2025EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding361,853,880
10 Day Avg. Volume10,305,404
30 Day Avg. Volume11,359,291
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.43
Enterprise Value/Revenue1.36
Enterprise Value/Gross Profit6.58
Enterprise Value/Ebitda-0.91
Forecast
1Y Price Target
$10.67Price Target Upside428.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
International ApprovalsAMTAGVI approved in Canada for advanced melanoma, granting market authorization for the therapy.
Revenue GrowthThe total 2Q25 product revenue of $60 million is in line with estimates and represents a 93% increase compared to the same period in 2024.
Strategic RestructuringIovance is entering a strategic restructuring estimated to save approximately $100 million annually, reduce cash burn, and improve gross margins without significant changes to the clinical pipeline.
Bears Say
Lack Of CatalystsThe stock was down approximately 35% in after-hours trading due to lackluster revenue and a lack of concrete catalysts or milestones in the near term.
Regulatory ChallengesIOVA withdrew its application to the EMA following lack of alignment during discussions on clinical data.
Revenue MissThe stock reacted negatively after-hours to 2Q results due to a revenue miss mainly from IL-2.
Iovance Biotherapeutics News
IOVA FAQ
What was Iovance Biotherapeutics Inc’s price range in the past 12 months?
Iovance Biotherapeutics Inc lowest stock price was $1.64 and its highest was $12.51 in the past 12 months.
What is Iovance Biotherapeutics Inc’s market cap?
Iovance Biotherapeutics Inc’s market cap is $767.13M.
When is Iovance Biotherapeutics Inc’s upcoming earnings report date?
Iovance Biotherapeutics Inc’s upcoming earnings report date is Nov 06, 2025 which is in 40 days.
How were Iovance Biotherapeutics Inc’s earnings last quarter?
Iovance Biotherapeutics Inc released its earnings results on Aug 07, 2025. The company reported -$0.33 earnings per share for the quarter, missing the consensus estimate of -$0.283 by -$0.047.
Is Iovance Biotherapeutics Inc overvalued?
According to Wall Street analysts Iovance Biotherapeutics Inc’s price is currently Undervalued.
Does Iovance Biotherapeutics Inc pay dividends?
Iovance Biotherapeutics Inc does not currently pay dividends.
What is Iovance Biotherapeutics Inc’s EPS estimate?
Iovance Biotherapeutics Inc’s EPS estimate is -0.25.
How many shares outstanding does Iovance Biotherapeutics Inc have?
Iovance Biotherapeutics Inc has 361,853,880 shares outstanding.
What happened to Iovance Biotherapeutics Inc’s price movement after its last earnings report?
Iovance Biotherapeutics Inc reported an EPS of -$0.33 in its last earnings report, missing expectations of -$0.283. Following the earnings report the stock price went down -20.076%.
Which hedge fund is a major shareholder of Iovance Biotherapeutics Inc?
Currently, no hedge funds are holding shares in IOVA
Iovance Biotherapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.67 (428.22% Upside)
$10.67 (428.22% Upside)
Blogger Sentiment
Bullish
IOVA Sentiment 66%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Decreased
By 12.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.30%
12-Months-Change
Fundamentals
Return on Equity
-53.16%
Trailing 12-Months
Asset Growth
-5.90%
Trailing 12-Months
Company Description
Iovance Biotherapeutics Inc
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
IOVA Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong positive outlook with significant revenue growth, successful adoption of Amtagvi, and strategic restructuring to improve profitability. Despite increased expenses and a setback in European regulatory strategy, the overall momentum and achievements outweigh the challenges.View all IOVA earnings summariesIOVA Stock 12 Month Forecast
Average Price Target
$10.67
▲(428.22% Upside)
Technical Analysis
KalVista Pharmaceuticals
―
Vir Biotechnology
―
Immatics
―
Nuvation Bio
―
Amylyx Pharmaceuticals Inc
―
Ownership Overview
0.32% Insiders
12.60% Mutual Funds
20.22% Other Institutional Investors
54.80% Public Companies and
Individual Investors